Literature DB >> 12875580

Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo.

Roberto Albera1, Roberto Ciuffolotti, Maurizio Di Cicco, Giuseppe De Benedittis, Irene Grazioli, Gabriella Melzi, Eugenio Mira, Eugenio Pallestrini, Desiderio Passali, Agostino Serra, Claudio Vicini.   

Abstract

OBJECTIVE: The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs.
MATERIAL AND METHODS: Patients with recurrent vertigo of peripheral vestibular origin and who were severely handicapped by vertigo were randomized to an 8-week course of treatment with oral BH 48 mg daily or oral FL 10 mg daily. The efficacy endpoints were the total DHI score and the physical, functional and emotional subscores.
RESULTS: Fifty-two patients completed the study. After 8 weeks of treatment the mean total DHI score and the physical subscore were significantly lower in the BH group compared to the FL group (7.5 and 3.6 points, respectively). The mean total DHI score as well as the three subscores decreased significantly after 4 and 8 weeks in both treatment groups.
CONCLUSION: This study showed that at 8 weeks BH is significantly more effective than FL in terms of improving the total DHI score and the physical subscore. It was also established that the DHI is a useful and reliable method for evaluating the efficacy of antivertigo drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875580     DOI: 10.1080/00016480310001475

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  12 in total

1.  Therapeutic strategies in the treatment of Menière's disease: the Italian experience.

Authors:  Nicola Quaranta; P Picciotti; G Porro; B Sterlicchio; G Danesi; P Petrone; Giacinto Asprella Libonati
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-11       Impact factor: 2.503

2.  Betahistine: a retrospective synopsis of safety data.

Authors:  Sabine Jeck-Thole; Wolfgang Wagner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Does betahistine treatment have additional benefits to vestibular rehabilitation?

Authors:  Hale Karapolat; Nese Celebisoy; Yesim Kirazli; Cem Bilgen; Sibel Eyigor; Sercan Gode; Aycan Akyuz; Tayfun Kirazli
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-21       Impact factor: 2.503

4.  Management of vestibular migraine.

Authors:  Alexandre R Bisdorff
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

5.  Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study.

Authors:  Ales Hahn; Miroslav Novotný; Penko M Shotekov; Zdenek Cirek; Irene Bognar-Steinberg; Wolfgang Baumann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 6.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

Review 7.  [Menière's disease : evidence and controversies].

Authors:  M Westhofen
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

8.  The evaluation of ozone and betahistine in the treatment of tinnitus.

Authors:  Onur Sönmez; Ismail Külahlı; Alperen Vural; Mehmet Ilhan Sahin; Mesut Aydın
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-26       Impact factor: 2.503

9.  Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.

Authors:  D Monzani; M R Barillari; M Alicandri Ciufelli; E Aggazzotti Cavazza; V Neri; L Presutti; E Genovese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-12       Impact factor: 2.124

10.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.